Inovio Pharmaceuticals, Inc. (INO)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Company performance

Current Price

as of Jan 07, 2025

$2.28

P/E Ratio

N/A

Market Cap

$82.31M

Jan 22, 2024Feb 26, 2024Apr 1, 2024May 2, 2024Jun 5, 2024Jul 9, 2024Aug 8, 2024Sep 12, 2024Oct 17, 2024Nov 21, 2024Jan 7, 2025$300.00$350.00$400.00$450.00$500.00$550.00
  • ERIE
Description

Inovio Pharmaceuticals, Inc. engages in the provision of designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus. Its product pipeline includes VGX-3100, INO-3107, INO-5410, INO-4800, and PENNVAX-GP. The company was founded by David B. Weiner on June 29, 1983 and is headquartered in Plymouth Meeting, PA.

Metrics

Overview

  • HQPlymouth Meeting, PA
  • SectorHealth Technology
  • IndustryPharmaceuticals: Major
  • TickerINO
  • Price$2.28+18.13%

Trading Information

  • Market cap$82.31M
  • Float98.86%
  • Average Daily Volume (1m)1,787,662
  • Average Daily Volume (3m)820,070
  • EPS-$4.48

Company

  • Revenue$0.20M
  • Rev growth (1yr)-100.00%
  • Net income-$25.17M
  • Gross marginN/A
  • EBITDA marginN/A
  • EBITDA-$26.58M
  • EV$90.29M
  • EV/Revenue443.89
  • P/EN/A
  • P/S315.42
  • P/B0.81
Documents